Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $35.77, for a total transaction of $7,154,000.00. Following the sale, the chief executive officer directly owned 1,599,154 shares of the company’s stock, valued at approximately $57,201,738.58. This represents a 11.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Monday, July 27th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.95, for a total transaction of $6,990,000.00.
• On Wednesday, June 24th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00.

Roivant Sciences Stock Down 0.3%

ROIV stock opened at $34.52 on Wednesday. Roivant Sciences Ltd. has a twelve month low of $11.94 and a twelve month high of $37.97. The stock has a market cap of $24.93 billion, a P/E ratio of -65.13 and a beta of 1.12. The business’s 50-day moving average price is $35.27 and its 200-day moving average price is $31.04.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The company had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. On average, equities research analysts expect that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ROIV. Jefferies Financial Group Inc. purchased a new stake in shares of Roivant Sciences during the 4th quarter worth approximately $76,272,000. Nicholas Investment Partners LP increased its holdings in shares of Roivant Sciences by 13.9% in the 4th quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company’s stock worth $6,073,000 after buying an additional 34,235 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Roivant Sciences in the 1st quarter worth about $3,957,000. Baader Bank Aktiengesellschaft purchased a new stake in shares of Roivant Sciences during the 4th quarter valued at about $1,029,000. Finally, Bank of America Corp DE raised its position in shares of Roivant Sciences by 8.0% during the 1st quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock valued at $87,638,000 after buying an additional 235,493 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ROIV shares. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research note on Tuesday, August 25th. Leerink Partners set a $42.00 price target on Roivant Sciences in a report on Thursday, May 21st. Bank of America restated a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. Guggenheim upped their price objective on Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, HC Wainwright reissued a “buy” rating and set a $41.00 target price on shares of Roivant Sciences in a research note on Friday, August 28th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $35.14.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.